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1.  Introduction 
 
1.1 Background to study 
Prostate cancer is a major public health issue. The natural ageing of the population, combined with 
the continued and widespread use of improved diagnostic tests such as serum prostate specific 
antigen (PSA), are resulting in an increase in the numbers of men diagnosed with localised prostate 
cancer. In England and Wales, it is the second most common malignancy in men, with 6,179 new 
cases registered in 1971, rising to 17,210 in 19931. Screening to identify prostate cancer while it is 
confined to the gland has provoked much public and scientific attention and there is intense debate 
about its role in improving men’s health.  While there are strong advocates of screening, the 
findings from most reviews of the scientific evidence conclude that there is insufficient evidence to 
recommend population screening because of the lack of evidence that prostate cancer screening 
would improve the quantity and quality of men’s lives2-5. Particular concerns relate to the lack of 
knowledge about the natural history of screen-detected disease, and the lack of evidence about the 
effectiveness of treatments.   
 
Finasteride reduces the risk of prostate cancer in the men with a low PSA and negative biopsy6 but 
side effects made its use on a long term community basis unfeasible and it has not been widely 
prescribed for prostate cancer prevention. Dietary prevention could be an alternative, and 
promising candidates have been identified in the recent WCRF systematic review of observational 
studies7, with some of the strongest evidence emerging for lycopene. The only ongoing trials in this 
area are of Vitamin E and selenium (the SELECT trial)8 in men with an initial PSA of less than 
4.0ng/ml and a US trial of selenium with HGPIN patients.9 Ideal dietary modification would 
inhibit both tumour initiation and growth of small cancer foci. Laboratory and observational 
studies indicate that lycopene and green tea may both possess this dual action but robust trial 
evidence is urgently required.10 
Lycopene is a carotenoid constituent of tomatoes with potent cytostatic activity. Tomato 
consumption was associated with a 31% reduction in prostate cancer risk7 and lycopene reduced in 
vivo DNA damage.10 A recent small trial in high risk men in Tobago has shown lycopene 
supplementation to be acceptable and tolerable in that setting.11 A recent review of lycopene 
concluded that ‘further well-designed studies are necessary to establish the role of tomatoes and 
tomato products in the prevention and therapy of prostate cancer’.12 Green tea contains active 
polyphenols including the catechins epigallocatechin-3-gallate (EGCG).13 An effect of green tea in 
reducing prostate cancer risk is supported by some observational evidence.7 A small trial of green 
tea in HGPIN patients showed good tolerability at 12 months.13 Initial evidence suggests that these 
phytochemicals may modulate insulin-like growth factor (IGF-1 and IGFBP-3) levels which are 
associated with prostate cancer risk.14  
 
1.2  Benefits to the NHS 
Prostate cancer is a major public health problem with significant mortality and morbidity. The 
opportunities for prevention currently are few, with the value of prostate cancer screening awaiting 
randomised trials including ProtecT (Prostate Testing for Cancer and Treatment), a multi-centre 
treatment trial preceded by community-based prostate specific antigen (PSA) testing with over 
85,000 men enrolled. The ProtecT study also identifies men with PSA values just below the biopsy 
threshold (3.0 ng/ml) (c.2,400) and others with negative biopsies (c.4,300). These men have an 
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elevated risk of prostate cancer as they include those with precursor conditions (e.g. HGPIN) and 
small cancer foci undetected by biopsies. 
 
Dietary prevention would be an important clinical development as there is no guidance currently 
available to reduce prostate cancer risk for these groups. There is an increasing rate of detection in 
the general population through opportunistic PSA screening. This represents an increasing burden 
on NHS resources, and is becoming a serious economic and ethical problem.  While the need for 
randomised controlled trials of dietary prevention is not in doubt, difficulties in mounting such 
trials called for new methodological approaches which were employed in the ProtecT study – 
methods which incorporates more fully the participant’s perspective.  
 
2. Trial design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 250 
Invitations  
men 50–69 yrs  
150 (60%) 
Clinic attendees 
126 (84%) 
Enrolled 
Lycopene 
rich diet 
42 
Lycopene 
capsules 
42 
Placebo 
capsules  
42 
Randomisation 
1 and 6 months research data collection 
Green tea 
capsules 
42 
Placebo 
capsules 
42 
Green tea 
drink 
42 
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3. Aims  
 
This study aims to investigate the feasibility of recruiting men identified with an increased risk of 
prostate cancer from the ProtecT study into a randomised trial of dietary modification.  The study 
also aims to investigate whether dietary modification or supplementation results in elevated serum 
levels of the biological active dietary agents.  
 
4.  Objectives 
 
The primary objective is to assess serum lycopene and epigallocatechin-3-gallate (green tea) 
levels at six months following randomisation.  The secondary objectives are to evaluate: 
 trial recruitment and randomisation rates 
 intervention tolerability 
 compliance 
 trial retention 
 PSA values 
 dietary compliance with recommendations  
 weight and body mass index 
 attitudes and views of men and their spouses about dietary modification and participation in 
long term 
 
5.  Study design 
 
The study consists of two major components: 
1) A 2x3 factorial design double blind RCT of dietary modification with green tea and lycopene 
2) In-depth qualitative interviews which will investigate men’s views about disease prevention, 
diet and prostate cancer, their willingness to modify diet or take supplements and attitudes 
towards participation in long-term trials of dietary modification. 
 
6.  Ethical aspects 
 
6.1  Ethics 
The study will be conducted according to the Declaration of Helsinki 1964, as revised in Tokyo 
1975, in Venice 1983 and by the 41st World Medical Assembly, Hong Kong, September 1989. 
 
6.2 Ethics Committee Approval (CC) 
Approval has been obtained from Trent MREC for the study (08/H0405/61). The principal 
investigator at each clinical centre (CC) will submit the protocol for approval for research 
governance. The application for approval will include a copy of the participant consents, 
information sheets and other relevant materials.  
 
6.3  Participant Consent (CC) 
Persons asked to participate in this research are entitled to choose whether or not to take part. Their 
decision will be voluntary and they will be competent to understand what is involved. Consent 
forms will be designed to assure the protection of their rights. 
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Participants will receive both written and verbal information. The written information has been 
approved by the medically qualified investigators. The verbal explanation to the participant will be 
performed by the research nurse under the supervision of the medically qualified investigators. 
The verbal explanation will cover all the elements specified in the written information provided for 
the participant. The participants will be informed of the aims, methods, anticipated benefits and 
potential hazards of the study, including any discomfort it may entail. 
 
The participant will be given every opportunity to clarify any points he does not understand and if 
necessary ask for more information. At the end of the discussion the participant will be given time 
to reflect. The participant is at liberty to withdraw their consent to participate at any time, without 
prejudicing any future medical care. 
 
The research nurse will then obtain the participants freely given written informed consent. Both 
investigators and participants retain copies of the signed consent forms. 
 
6.4  Investigator responsibilities (CC) 
The principal clinical investigator at each centre will be responsible for the clinical conduct of the 
study staff. The clinical investigators will maintain a Trial Master File including a list and CVs of 
appropriately qualified persons to whom they have delegated significant trial-related duties. The 
investigator will be responsible that all such identified persons will be thoroughly familiar with the 
protocol and study procedures, as well as being aware of the principles of good clinical practice 
(GCP) (MRC Guidelines for Good Clinical Practice in Clinical Trials, MRC 1998). The research 
nurse shall have responsibility for the efficient operation of the study to GCP guidelines. 
 
7.  Study population 
 
Participants will be recruited through general practices that have participated in the ProtecT study 
of treatment for localised prostate cancer (ISRCTN20141297). 
 
8.  Inclusion and exclusion criteria 
 
Inclusion criteria 
 Age 50-691 years on the date of preparation of the list at the general practice of potential 
participants for the ProtecT study 
 Male gender 
 ProtecT participants with a PSA test between 2.0 to 2.95 ng/ml or a PSA level of at least 3.0 
ng/ml with a negative biopsy (10 core procedure) from the ProtecT study 
 Enrolled in the ProMPT study and willing to be contacted about further studies 
 Able to give informed written consent to participate 
 Registration with the participating general practice  
 
Exclusion criteria 
This trial is of pragmatic design. Therefore, exclusion criteria will be kept to the minimum possible.  
All ProtecT participants are without major co-morbidities, other cancers or prior 
prostate malignancy. Participants will be excluded with: 
 A PSA ≥20 ng/ml (indication of prostate cancer or prostatitis) 
 History of allergic reactions to green tea or lycopene containing products (including 
guava, watermelon) 
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 Concurrent medication with finasteride or dutasteride (elevates PSA values) 
 
9.  Recruitment of participants  
 
9.1 Information to general practices (CC and SMed) 
Practices will be contacted by the trial coordinator and the GPs and practice manager will be 
briefed about the study and given the protocol. The study nurse will subsequently visit the practice 
to establish suitable accommodation for the study clinics and to liase with practice staff.  
9.2  Participant invitation procedures (CC and SMed) 
A participant information sheet outlining the study will accompany the invitation letter 
(Information Sheet 1).  All individuals invited to participate in the trial will be allocated a unique 
study number by SMed. Address labels will be generated and invitations to join the study sent to 
men in manageable batches. Letters are mailed out from the study office on the study notepaper.  
The reply slips are returned to Social Medicine. The names and addresses of men indicating their 
willingness to join the study will be updated on the project database along with the date on which 
the reply slip was returned. Men who telephone and indicate either their willingness to participate 
or refusal are recorded in the same way as for letters.  Those men who do not reply to the initial 
letter or who decline to participate on the reply slip will have no follow-up.  
The study secretary will arrange appointments for these men and manage the clinic lists, including 
rearranging appointments where necessary. The dates and times of the clinics and attendees will 
also be entered into the study database. Persons who do not/can not attend their intended 
appointment will be contacted by telephone and a further appointment organised with details 
recorded on the database. Should they not attend on 2 occasions it will be assumed that they no 
longer wish to participate and this will be documented on the study database. The lists of 
appointments and place of the clinics will also be recorded on the database. 
9.3 Participant visit schedule (CC) 
 All individuals: enrolment visit 
 If eligible for randomisation:  research follow-up at one and six months after randomisation 
 
10. Recruitment clinics (RC) 
 
Recruitment will be performed mostly at the participating general practices, but also at the 
hospital. On attendance the research nurse (previously carefully instructed by the study team and 
working from a detailed script utilised in the training programmes) will provide verbal 
information on the study aims and design.   
 
Prostate cancer risk and prevention will be discussed and it will be made clear that participation in 
the project is purely voluntary and the participant will be free to decline without prejudicing their 
future care.  Participants will be given the opportunity to ask questions. Those who decline to 
participate will be free to leave and will be thanked for attending.  
 
The research nurse will ensure that all men willing to participate in the trial are eligible to do so 
(using the eligibility criteria detailed earlier and in the RC schedule). Those ineligible to participate 
will have the reason for ineligibility explained to them and they will be thanked for their 
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attendance and support of the project. Men who wish to participate will be asked to give written, 
witnessed consent (Consent Form 1).  A copy of all signed consent documents will be given to 
participants.  
 
10.1  Initial data collection at the Recruitment Clinic (RC) 
 
A. Research nurse  
1. Discusses study information, and requests consent to participate in the ProDiet study (Consent 
1). 
 Consent form 1 is for consent to enter the study and take blood for the PSA test  
 Consent 1  (one copy) are given to participant  
 A cross is placed in boxes of sections the participant does not consent to, initialled by the 
participant  
 
2. Completes the S1 Schedule for Recruitment Clinic containing: 
 baseline socio-demographic data; age, socio-economic status, ethnicity  
 exclusion criteria checklist 
 a checklist to discuss with participants describing the ProDiet study 
 any recent PSA test results subsequent to the ProtecT study tests   
 
3. Completes a single page version of the data entry form (RC Proforma) about the attendance at 
the clinic and outcome. The RC Proforma is entered onto the study computer at the earliest 
opportunity by the study secretary, including any other comments regarding the man or the 
appointment. 
 
4. Records on the RC  Schedule the weight, height, blood pressure and pulse as well as the 
study instrument number of the scales and blood pressure monitor. If the blood pressure is 
above a hypertensive level agreed with the current practice (identified by the lead nurse in 
initial visits) the participant will be advised to have the blood pressure checked again by the 
practice nurse and the practice will be informed of the reading.   
5. Takes a baseline PSA test. Result sent by post to participant and GP, depending on normal 
result (PSA letter_normal and letter_normal GP) or raised PSA (PSA letter_raised and PSA 
letter_raised GP). 
 
B. Participants  
1. Men complete a study questionnaire (FTQ1) on urinary symptoms (ICSmaleSF questionnaire16), 
general health status [Hospital Anxiety and Depression scale17 (HAD) and Profile of Moods 
States]18  which they may return in the post if necessary, using a freepost envelope.  
2. Men also complete a questionnaire (FTQ1a) about their current diet [Food Frequency 
Questionnaire]  
 
 
11.  Randomisation (CC) 
The main purpose is to provide the participant with sufficient information to allow him to decide 
whether or not he is willing to be randomised to the dietary interventions. The study nurse 
emphasises the need for a trial, describes the advantages and disadvantages of each of the dietary 
options and explains the purposes of randomisation. The information content and delivery builds 
on methodology gained from the ProtecT study and the nurse will work to a detailed but flexible 
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script. Men should not undergo randomisation unless they are willing to receive any of the dietary 
options, including placebo, and at that stage randomisation should then proceed.   
 
Once the participant has agreed to be randomised, the nurse will telephone SMed to log the man’s 
details. The nurse will open the next numbered sealed treatment pack.  Treatment packs will 
contain a randomly allocated dietary intervention described in section 11.2.  The treatment packs 
will be prepared by SMed (overseen by the principal study statistician) with the research nurse 
blind to the treatment pack contents. 
11.1  Stratification variable 
ProtecT RC PSA test (two strata:  <3.0 ng/ml and 3.0 – 19.99 ng/ml) 
11.2 Dietary interventions 
The nurse will randomise men between two factors with three levels: 
1. Lycopene: 
a) dietary advice regarding a daily portion of cooked tomatoes (rich in lycopene) plus matched 
placebo capsules (deleted) 
b) tomato-derived lycopene supplement capsules daily  with control dietary advice 
recommending five daily portions of fruit and vegetables (‘healthy diet’)(deleted) 
c) healthy dietary advice plus (deleted)  matched placebo capsules (control) 
2.   Green tea: 
d) green tea capsules at 800 mg daily  
e) matched placebo supplement capsules (control) 
f) dietary advice regarding green tea drinking 
 
12. Research data collection (CC and SMed) 
 
12.1  Evaluation of recruitment and attrition in follow-up (CC and SMed) 
Records will be kept of the response rates at all stage of the study and those not completing follow-
up where the research nurse will try to obtain a reason for the loss to follow-up. 
 
12.2  Adverse events (CC) 
 
An adverse event (AE) is defined as any untoward medical occurrence in a participant which does 
not necessarily have a causal relationship with this treatment.  
 
Adverse events resulting from any of the dietary interventions will be recorded by the nurse on the 
follow-up research schedule and by participants on an adverse events checklist at the time of the 
occurrence and returned in a prepaid-envelope to the study office. 
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Serious AE are defined by the MRC GCP guidelines: 
 
Serious adverse events includes any untoward medical occurrence that:  
 results in death 
 is life-threatening 
 requires in-patient hospitalisation or prolongation of existing hospitalisation 
 results in persistent or significant disability or incapacity 
 
All serious adverse events (SAE) should be notified within 48 hours of occurrence to Professor 
Hamdy and the study co-ordinator.  Death notification should occur within 24 hours of the study 
team learning of the event. SAE probably related to participation in the trial are reported to the 
MREC within 15 days on the COREC SAE proforma. There may be a requirement from the local 
R&D office to report SAE, and this should be established by a centre. 
 
Adverse events reported from literature for lycopene and green tea, although causality was 
frequently not established due to the non-randomised study designs. 
 
Adverse event Lycopene extract Green tea (extract and drink) 
Nausea Yes Yes 
Heartburn No Yes 
Diarrhoea Yes Yes 
Muscle cramps No Yes 
Nocturia No Yes 
Dyspnea No Yes 
Headache No Yes 
Hypertension No Yes 
Insomnia No Yes 
Fatigue No Yes 
 
 
12.3  Participant data collection in follow-up (SMed and CC) 
Participants will be given the ProDiet study telephone number for any questions or advice 
following randomisation. Research data collection for the participants will be at one and six months 
after the date of randomisation.  Men will be invited to follow-up clinics with the study nurse by 
letter and telephone. Men will be asked to complete the questionnaire with the instruments used at 
baseline on anxiety and depression and urinary symptoms and dietary measures. There will be 
additional questions on compliance and satisfaction with the intervention, as well as any other 
dietary or vitamin supplementation be utilised by the participants. The nurse will also repeat the 
anthropometry and blood samples taken at recruitment. The nurse will take details of any prostate 
cancer related clinical information of relevance, e.g. additional PSA tests or biopsies conducted 
since randomisation. A ProDiet  website will give details of the study including methods for the 
preparation of the lycopene-rich foods. Men unable to attend follow-up appointments will be 
followed-up by telephone where possible. Men can also provide email and/or mobile phone 
numbers to the study team. These contacts will be used for appointment and questionnaire 
reminders and to assist intervention adherence by the study team in between appointments.. 
Participants will receive a small token, e.g. a pen or a fridge magnet for contributing to the study. 
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If the participants do not attend the follow-up clinics, the questionnaire will be posted to 
participants after any changes of address or contact status are reviewed on the database by the 
clinical centres. A reminder is sent out 3 weeks after non-return of the questionnaire. The nurse will 
attempt to identify any PSA tests as part of clinical care if the participant does not attend follow-up 
clinics and any evidence of serious adverse events. 
 
 
13.  Outcome measures 
 
13.1   Primary outcome  
The primary outcome will assess serum lycopene and epigallocatechin-3-gallate (green tea) 
levels at six months following randomisation.  
  
13.2  Secondary outcomes 
The secondary outcomes will assess: 
 trial recruitment and randomisation rates (measured at each stage of the study flowchart) 
 intervention tolerability (adverse event reporting during the six months of follow-up) 
 compliance (returned tablet counts and self reported counts at six months) 
 trial retention (participants completing the six month follow-up and the questionnaires) 
 PSA values (measured at baseline and six months) 
 dietary compliance with recommendations (dietary questionnaire completed at six months and 
participant data reporting dietary change) 
 weight and body mass index (measured at one and six months) to assess whether the 
interventions have beneficial or deleterious effects on weight 
 blood pressure (measured at one and six months) to assess whether there are any overall health 
benefits to the healthy diets 
 attitudes and views of men and their spouses about dietary modification and participation in 
long term (qualitative interviews conducted throughout the study) 
 Anxiety, depression and psychological state - measured by the Hospital Anxiety and 
Depression Scale17 and the Profile of Moods States18 
 Urinary symptoms - measured by the ICSmaleSF questionnaire17, which includes voiding and 
incontinence scores, nocturia, frequency and urinary-specific quality of life care data sources. 
 
 
14.  Qualitative research (SMed) 
 
In-depth qualitative interviews will investigate men’s views about disease prevention, diet and 
prostate cancer, their willingness to modify diet or take supplements and attitudes towards 
participation in long-term trials of dietary modification, including undergoing prostate biopsies (a 
potential main trial outcome). Purposive theoretical sampling will select trial participants and 
refusers as well as compliant and noncompliant individuals. Men’s spouses/partners and clinicians 
will also be interviewed as they may influence men’s attitudes towards dietary prevention. 
Interviews will be fully transcribed and subjected to thematic analysis using specialist software 
(ATLAS-ti) to identify barriers to a successful dietary intervention and opportunities to overcome 
them. This research will be conducted and analysed by Dr Kerry Avery who is highly experienced 
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in this methodology and holds a DoH fellowship to investigate dietary change in prostate cancer 
patients (tel: 0117 9287272). Dr Jeremy Horwood, an experienced qualitative researcher will also 
contribute to the qualitative research component. 
 
Non-responders 
All non-responders would receive an explanatory letter with the short questionnaire which 
would also invite them to a telephone interview by returning a reply slip in a reply paid 
envelope to the study office. An experienced qualitative researcher would then contact those 
men agreeing to an interview and conduct interviews by telephone or in person, as men prefer. 
Interviews would utilise a shortened version of the main study topic guide. We would not send 
reminder letters regarding return of the questionnaire or interviews 
 
15.  Data management and security 
 
A unique file identified by the study number will be maintained for participants.  All data recorded 
on paper relating to the participant will be located in these files. A list will be maintained at each 
centre of staff authorised to make alteration to the study records, including the study database. 
 
Data obtained on paper will also be entered onto and maintained on a ‘Microsoft Access’ database. 
Information capable of identifying individuals and the nature of treatment received will be held in 
the database with passwords restricted to ProDiet study staff.  Data from computerised sources 
will be converted to ‘Access’ databases and hard copies will be maintained in the relevant 
participants file in locked filing cabinets. Information capable of identifying participants will not be 
removed from SMed or clinical centres or made available in any form to those outside the study. 
All data held in SMed will conform to the Department Data Security Policy and Department 
Compliance with the Data Protection Act policies. 
 
16.  Management and ethical considerations and study organisation  
 
A Trial Steering Committee will oversee the trial. Written records will be taken of each meeting and 
copies held by the study coordinator. A Data Monitoring and Safety Committee will not be 
convened as there are no planned interim analysis and the primary endpoints are not clinical. 
Serious Adverse Events would be reported to MREC.  Some tolerability data has already published 
on these dietary agents. 
 
 16.1  Trial Steering Committee 
The TSC will have an independent Chairman, Dr Steven Oliver, Senior Lecturer in Population 
Health at the University of York whose research interests include dietary prevention and prostate 
cancer. The TSC will comprise the Co-PIs, Dr Merran Toerran, an independent qualitative 
researcher with clinical trials experience from the University of York and a urologist, Mr Derek 
Rosario from the University of Sheffield. The final composition will be determined by the TSC 
Chairman. The TSC will meet every six months. 
 
16.2  Publication policy 
Reports will be produced as requested by CRUK.  Papers will be prepared for publication in 
general and urological peer-reviewed journals.  The findings will also be presented at national and 
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international conferences. All publications using study data must be approved by the PIs prior to 
submission of the publication and they retain the decision to publish or communicate study results  
 
16.3  Departures from protocol 
It is important to keep participant withdrawals from the trial to a minimum but; 
 a participant may be withdrawn from the study by their general practitioner or the study team 
at any time should it be considered detrimental to the participant to continue. 
 a participant may withdraw from the study at any time without prejudice to his subsequent 
treatment. 
 
Participants who fail to attend appointments will be contacted by telephone and letter, to 
encourage them to attend, to arrange alternative appointments and to determine reasons for 
withdrawal.  Reasons for withdrawal will be fully documented on the study database and adverse 
event forms completed if applicable. If participants switch to different interventions post-
randomisation this will be analysed by a per protocol secondary analyses. If data is missing on 
participants, a sensitivity analyses will be conducted, but this is less powerful than having the data. 
 
16.4 Organisation of study documentation 
All clinical centres will have an investigators’ Trial Master File which will include all relevant 
information and documentation for the trial. This will include the protocol, MREC approval, 
financial agreements, CVs of all staff involved in the trial, and any correspondence or emails 
received pertaining to the study. It will be the responsibility of the research nurse at each site to 
maintain this file. 
17.  Project milestones 
On commencement of funding: 
Staff appointments 
Two months: 
Qualitative research commences 
Three months: 
Recruitment for two months 
Four months: 
One month follow up PSA tests 
Compliance assessments 
Nine months: 
Six month follow-up participant visits commence 
EGCG (green tea) and lycopene serum samples taken and analysed 
Participant follow-up questionnaire 
Twelve months: 
Follow-up completed, including compliance assessments 
Data cleaning 
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Fifteen months: 
Qualitative research analysis completed 
Analysis of primary and secondary outcomes 
Eighteen months: 
Final report to CRUK 
Draft publication for peer reviewed journal
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APPENDIX 1: Sample size calculations and statistical analyses 
 
Sample size 
Around 250 men will be invited to take part until 126 men agree to enrol - this would give an 
acceptance rate of 50% with a 95% confidence interval of 44% to 56%. If 126 men are enrolled, the 
study will have 90% power (5% significance) to detect a 67% increase in serum values of lycopene 
and EGCG between the control and intervention groups (including accommodation for the skewed 
distribution of measures). 
 
Analyses plan 
The analyses will be conducted at the end of the study, i.e. the completion of the six month data 
collection and analyses of serum measures. The analysis of the primary outcomes, serum lycopene 
and EGCG, will compare mean levels between the three levels of the corresponding dietary factor 
(lycopene and green tea interventions respectively) with appropriate accommodation of positively 
skewed distributions using bootstrap methods. The analysis will be repeated for one month and six 
month follow-up assessments. For secondary outcomes, overall trial recruitment and 
randomisation rates will be calculated with 95% confidence intervals. Comparison of tablet counts 
between groups receiving active supplementation and the placebo groups for each factor in turn 
will indicate whether tolerability is affecting adherence. PSA levels will be investigated in the same 
manner as the primary outcomes but with the first PSA level measured during diagnosis being 
included as a covariate, with a potential improvement in statistical power. Interaction between the 
two factors will be investigated for each outcome, as the factorial design will be an efficient 
approach if  there is none apparent and both dietary factors are carried over to the main trial. There 
is no existing evidence of biological interaction between the two dietary factors and investigation of 
this is required. There may be an interaction for measures of compliance, as individuals intolerant 
of one dietary factor may stop increasing their intake of both. 
 
Subgroup analyses 
Recruitment and randomisation rates as well as the effects of supplementation on the primary and 
secondary outcome will be compared between the two groups of men recruited, i.e. those with a 
PSA of between 2.5-2.9 ng/ml and those with a PSA ≥ 3.0ng/ml and a negative biopsy. 
